| Literature DB >> 24112365 |
Yoshihide Ueda1, Atsushi Yoshizawa, Yasuhiro Ogura, Aya Miyagawa-Hayashino, Hironori Haga, Tsutomu Chiba, Shinji Uemoto.
Abstract
Plasma cell hepatitis (PCH) is an idiopathic disorder characterized by plasma cell infiltration in the allografts of patients who have undergone liver transplantation. Although an increasing number of cases of PCH have been reported in liver transplant recipients with hepatitis C recurrence treated with interferon, it is unclear whether PCH is induced by interferon itself. Here, we describe the cases of two patients who developed PCH just after the termination of antiviral therapy for recurrent hepatitis C after living donor liver transplantation. Liver dysfunction appeared at 1 month in one patient and 2 months in the other patient after pegylated interferon plus ribavirin therapy, and liver histology showed interface hepatitis with plasma cell-rich lymphoid aggregates. Both patients recovered after steroid therapy and achieved sustained virological response. These cases suggest that PCH could be induced by the alteration of the immune condition resulting from the termination of antiviral therapy. PCH should be considered when the transaminase levels increase after antiviral therapy, and it should be carefully distinguished from hepatitis C relapse.Entities:
Keywords: antiviral therapy; hepatitis C; liver transplantation; plasma cell hepatitis
Year: 2013 PMID: 24112365 DOI: 10.1111/hepr.12243
Source DB: PubMed Journal: Hepatol Res ISSN: 1386-6346 Impact factor: 4.288